EP0716851B1 - Bath salt containing a magnesium salt and its manufacture process - Google Patents
Bath salt containing a magnesium salt and its manufacture process Download PDFInfo
- Publication number
- EP0716851B1 EP0716851B1 EP95119285A EP95119285A EP0716851B1 EP 0716851 B1 EP0716851 B1 EP 0716851B1 EP 95119285 A EP95119285 A EP 95119285A EP 95119285 A EP95119285 A EP 95119285A EP 0716851 B1 EP0716851 B1 EP 0716851B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bath salt
- bath
- weight
- magnesium chloride
- salt according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0275—Containing agglomerated particulates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
Definitions
- the present invention relates to a bath salt a content of magnesium salts and the process for its preparation this bath salt as free-flowing, not hygroscopic Granules.
- EP-B-0 439 640 describes agents for external use in the treatment of inflammatory skin diseases as well to weaken allergic inflammatory reactions of the Skin, which 1 to 30 wt .-% magnesium chloride but none Contain calcium salts and carrier substances.
- JP abstract 3-291 214 describes a bath additive that has a has a body-warming effect, but also rust protection has so that the bath stoves and bathtubs are not damaged become.
- This bath additive contains various chlorides, such as Sodium chloride, potassium chloride, magnesium chloride or calcium chloride, which are mixed with sodium carbonate, sodium succinate, Aluminum sulfate and sodium bicarbonate. Of these, 0.4 to 8 wt .-% are mixed to 1 wt .-% chloride. This suppresses the rust-releasing effect of the chlorides.
- the DR-PS 670 768 describes a for the preparation of brine baths suitable bath salt, which is made using gelatin, Agar-agar, tragacanth, gum Acaciae u. Like. As a binder Mixtures of table salt and carnallite contains the under Volume reduction are pressed together. The so obtained Bars, briquettes, plates or cubes are not more sensitive to moisture, but dissolve as usual Table salt in water without leaving any residue.
- JP abstract 63-44 515 describes a bath additive that predominates consists of sodium bicarbonate, with a certain Particle size distribution. This mixture is granulated.
- the object of the invention is a bath salt to provide high levels of magnesium chloride but does not contain significant amounts of calcium salts.
- a bath salt with a magnesium salt content which is characterized by is that it's as flowable, not hygroscopic Granules are present.
- This granulate consists of cores at least 30% by weight of magnesium chloride crystals but none substantial amounts of calcium salts, the granules are covered with a water-soluble but as Water vapor barrier film coating.
- this bath salt additional vitamin Add E and / or unsaturated fatty acids. Because this is lipophilic Substances are prepared for their admixture Bath salts have particular difficulties.
- Mixtures can also be used as effervescent agents and / or disintegrants of explosives used with effervescent aids become. All the usual dry aids come as effervescent aids Mixtures that do not contain calcium salts. Prefers the mixture of sodium hydrogen carbonate is used and citric acid. Substances are the main explosives in question, which swell strongly on contact with water. For this include dried agar and dried guar gum. Due to the strong expansion when it comes into contact with water these explosives help the effective components quickly dissolve in the bath water.
- the content thereof should preferably be more than 50 % By weight.
- vitamin E and / or unsaturated fatty acids is the content of the bath salt of magnesium chloride 55 to 95% by weight.
- vitamin E and / or unsaturated Fatty acids have a content between 0.5 and 10% by weight.
- Amounts of 1.5% by weight of vitamin E and 1% of unsaturated fatty acids have proven particularly successful.
- the content of explosives and / or shower aids are usually in the range between 2 and 10% by weight. A content of 5% by weight effervescent aid has proven particularly successful.
- the granulation is preferably carried out with an aqueous suspension of dl- ⁇ -tocopherol acetate in water-dispersible Shape.
- the unsaturated fatty acids are also preferred used as solubilized complexes with hydroalcohol.
- Preferred unsaturated fatty acids are linoleic acid, Linolenic acid and arachidonic acid are used. in principle but also come all other mono- or polyunsaturated Carboxylic acids in question during treatment of atopic eczema and psoriaris.
- This Substances can be sprayed on as an alcoholic aqueous solution and form after drying in the form of a film coating excellent protection against moisture.
- the bath salt according to the invention is, depending on the magnesium chloride content in quantities of 200 to 500 g the bath water (approx. 80 l) added.
- the bath water thus contains the magnesium chloride in concentrations of less than 1%. For that can but evenly over the entire skin over a longer period of time be included so that it can develop its effectiveness there can.
- Epidermal Langerhans cells are of crucial pathogenetic importance in inflammatory skin diseases. These cells are among the antigen-presenting cells. Their activity is largely determined by a surface enzyme, an ATPase. The inhibition of this enzyme causes an inhibition of the function of the ELZ and thus a reduced inflammatory reaction on the skin.
- the inhibitory effect of magnesium, the magnesium bath salt according to the invention and other comparable bath salts and table salt were determined. The results are summarized in Tables 1 and 2 below. Influence of magnesium alone and of various salt solutions on ATPase-positive epidermal Langerhans cells (ELZ) in skin preparations from Balb / c mice No.
- the epidermis was incubated with the above-mentioned salt concentrations at 37 ° C. for 1 h, and the ELZ per 1 mm 2 epidermis was subsequently determined. Inhibition of croton oil-induced ear edema by externals containing magnesium chloride (6 mice per group of animals) Animal group no.
- the salt according to the invention is produced by that first the magnesium chloride in crystalline form with the effervescent additives sodium hydrogen carbonate and citric acid is mixed. This mixture is mixed with an aqueous Suspension of dl- ⁇ -tocopherol acetate (water dispersible) and a hydroalcohol-solubilized complex of unsaturated Fatty acids (linoleic acid, linolenic acid and arachidonic acid) sprayed onto the powder mixture, this granulating becomes.
- This material is made with fine powdered magnesium lactate dusted and then with an aqueous solution of Vinyl pyrolidone-vinyl acetate copolymer and hydroxyethyl cellulose jacketed. After drying, there is a film coating formed, which protects the granules against humidity and gives it great stability. When entering into Water quickly dissolves the bath salt with slight foaming on.
- the granules were covered with four different film coatings sprayed and dried.
- Film coating solution 1 consisted of vinyl pyrolidone vinyl acetate Copolymer in aqueous solution in concentrations between 1 and 5% by weight. This film cover shows a very good one Water permeability.
- Film coating solution 2 additionally contained 0.1 to 2.5% by weight Hydrophobically modified hydroxyethyl cellulose.
- Film coating solution 3 contained vinylpyrolidone-vinyl acetate Copolymer 0.05 to 2.5 wt .-% ethyl cellulose. This The mixture was dissolved in 75% aqueous ethanol and sprayed.
- Film coating solution 4 contains vinylpyrolidone-vinyl acetate Copolymer 0.05 to 1.5 wt .-% hydrophobic pyrogenic Silicic acid as an aqueous suspension.
- Film coatings 2 to 4 showed good but different ones water vapor barrier effect.
- the composition has a further preferred preparation magnesium chloride 55.00% magnesium lactate 1.00% sodium bicarbonate 10.00% Vinyl pyrolidone-vinyl acetate copolymer 2.00% ethylcellulose 0.30% citric acid 5.00% tocopherol 1.20% Acharidonic acid, linoleic acid, linolenic acid 1.00% lactose 24.50%
- This preparation is made as described above and is stable in storage, readily soluble in water, good effective and perfectly tolerated.
Abstract
Description
Gegenstand der vorliegenden Erfindung ist ein Badesalz mit einem Gehalt an Magnesiumsalzen sowie das Verfahren zur Herstellung dieses Badesalzes als rieselfähiges, nicht hygroskopisches Granulat.The present invention relates to a bath salt a content of magnesium salts and the process for its preparation this bath salt as free-flowing, not hygroscopic Granules.
Die EP-B-0 439 640 beschreibt Mittel zur äußerlichen Anwendung bei der Therapie entzündlicher Hautkrankheiten sowie zur Abschwächung allergischer entzündlicher Reaktionen der Haut, welche 1 bis 30 Gew.-% Magnesiumchlorid aber keine Calciumsalze sowie Trägersubstanzen enthalten.EP-B-0 439 640 describes agents for external use in the treatment of inflammatory skin diseases as well to weaken allergic inflammatory reactions of the Skin, which 1 to 30 wt .-% magnesium chloride but none Contain calcium salts and carrier substances.
Als Mittel zur äußerlichen Anwendung werden neben Salben und Lotionen auch Lösungen, Zahncremes, Kopf- bzw. Körperwaschmittel, Kosmetika und Badezusätze genannt. Salben, Cremes und Lotionen gemäß EP-B-0 439 640 sind bereits mit großem Erfolg in den Handel gebracht worden. Insbesondere bei der Behandlung von Psoriasis (Schuppenflechte) und beim atopischen Ekzem (Neurodermitis) besteht das Bedürfnis als äußerliche Anwendung auch die Sole-Badetherapie durchzuführen.In addition to ointments and Lotions also solutions, toothpastes, head or body detergents, Called cosmetics and bath products. Ointments, creams and Lotions according to EP-B-0 439 640 are already very successful been put on the market. Especially in the treatment of psoriasis (psoriasis) and atopic Eczema (neurodermatitis) exists as an external need Application also to carry out brine bath therapy.
Zu diesem Zweck sind bereits Badesalzmischungen im Handel, die dem Wasser des Toten Meeres nachgestellt sind. Das Wasser des Toten Meeres enthält über 40 verschiedene Mineralien, welche nur mehr oder weniger für die Wirksamkeit des Gemisches verantwortlich sind. Sie enthalten stets erhebliche Mengen an Calciumsalzen, die jedoch die Wirkung stark abschwächen oder sogar nicht eintreten lassen.Bath salt mixtures are already on the market for this purpose, that mimicked the Dead Sea waters. The water of the Dead Sea contains over 40 different minerals, which only more or less for the effectiveness of the mixture are responsible. They always contain substantial ones Amounts of calcium salts that, however, severely weaken the effect or not even let in.
Gemäß EP-B-0 439 640 ist die wichtigste Komponente das Magnesium. Seine Wirksamkeit wird aber durch die Anwesenheit von Calciumionen deutlich verschlechtert oder sogar völlig unterdrückt. According to EP-B-0 439 640, the most important component is magnesium. However, its effectiveness is affected by the presence of Calcium ions significantly deteriorated or even completely suppressed.
JP-Abstract 3-291 214 beschreibt einen Badzusatz, der einen körpererwärmenden Effekt aufweist, jedoch auch Rostschutz aufweist, so daß die Badeöfen und Badewannen nicht beschädigt werden. Dieser Badzusatz enthält verschiedene Chloride, wie Natriumchlorid, Kaliumchlorid, Magnesiumchlorid oder Calciumchlorid, denen beigemischt werden Natriumcarbonat, Natriumsuccinat, Aluminiumsulfat und Natriumbicarbonat. Hiervon werden 0,4 bis 8 Gew.-% zugemischt auf 1 Gew.-% Chlorid. Hierdurch wird der rostauslösende Effekt der Chloride unterdrückt.JP abstract 3-291 214 describes a bath additive that has a has a body-warming effect, but also rust protection has so that the bath stoves and bathtubs are not damaged become. This bath additive contains various chlorides, such as Sodium chloride, potassium chloride, magnesium chloride or calcium chloride, which are mixed with sodium carbonate, sodium succinate, Aluminum sulfate and sodium bicarbonate. Of these, 0.4 to 8 wt .-% are mixed to 1 wt .-% chloride. This suppresses the rust-releasing effect of the chlorides.
Die DR-PS 670 768 beschreibt ein zur Bereitung von Solbädern geeignetes Badesalz, welches unter Verwendung von Gelatine, Agar-Agar, Tragant, Gummi Acaciae u. dgl. als Bindemittel Mischungen aus Kochsalz und Carnallit enthält, die unter Volumenverminderung miteinander verpreßt werden. Die so erhaltenen Tafeln, Briketts, Platten oder Würfel sind nicht mehr feuchtigkeitsempfindlich, lösen sich jedoch wie gewöhnliches Kochsalz in Wasser auf, ohne Rückstände zu hinterlassen.The DR-PS 670 768 describes a for the preparation of brine baths suitable bath salt, which is made using gelatin, Agar-agar, tragacanth, gum Acaciae u. Like. As a binder Mixtures of table salt and carnallite contains the under Volume reduction are pressed together. The so obtained Bars, briquettes, plates or cubes are not more sensitive to moisture, but dissolve as usual Table salt in water without leaving any residue.
JP-Abstract 63-44 515 beschreibt einen Badezusatz, der überwiegend aus Natriumhydrogencarbonat besteht, mit einer bestimmten Korngrößenverteilung. Dieses Gemisch wird granuliert.JP abstract 63-44 515 describes a bath additive that predominates consists of sodium bicarbonate, with a certain Particle size distribution. This mixture is granulated.
Aus Pharmazeutische Technologie, 4. Auflage, 1978, VEB Verlag Volk und Gesundheit, Berlin, Seiten 43 und 44 sowie Seiten 290 bis 293 sind beschrieben die Eigenschaft Hygroskopizität sowie die Herstellung von Granulaten. Es findet sich jedoch kein spezieller Hinweis auf Badesalze.From Pharmaceutical Technology, 4th edition, 1978, VEB Verlag Volk und Gesundheit, Berlin, pages 43 and 44 and pages 290 to 293 describe the property of hygroscopicity and the production of granules. However, it is found no special reference to bath salts.
Aus Fiedler, Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, 3. Auflage, 1989, Seite 1328 und Seiten 695 bis 696 ist bekannt, daß Vinylpyrrolidon-Vinylacetat-Copolymere unter der Bezeichnung Kollidon VA 64 unter anderem auch zur Herstellung von Tablettenüberzügen für feuchtigkeitsempfindliche Substanzen einsetzbar ist. Ein Hinweis auf Badesalz findet sich hierin jedoch nicht.From Fiedler, Lexicon of auxiliary substances for pharmacy, cosmetics and adjacent areas, 3rd edition, 1989, page 1328 and Pages 695 to 696 are known to contain vinyl pyrrolidone-vinyl acetate copolymers under the name Kollidon VA 64 under other also for the production of tablet covers for moisture-sensitive substances can be used. On However, there is no reference to bath salts here.
Die Erfindung hat sich die Aufgabe gestellt, ein Badesalz zur Verfügung zu stellen, welches hohe Mengen an Magnesiumchlorid aber keine wesentlichen Mengen an Calciumsalzen enthält.The object of the invention is a bath salt to provide high levels of magnesium chloride but does not contain significant amounts of calcium salts.
Diese Aufgabe ist ausgesprochen schwierig zu lösen, da Magnesiumchlorid stark hygroskopisch ist und bereits durch den Zutritt von Luftfeuchtigkeit zerfließt. Es ist somit nicht möglich, das Magnesiumchlorid in reiner Form trocken und rieselfähig zu halten.This task is extremely difficult to solve because of magnesium chloride is highly hygroscopic and already through the Admission of humidity dissolves. So it is not possible to dry the magnesium chloride in pure form and to keep free flowing.
Es ist jetzt gelungen, ein Badesalz mit einem Gehalt an Magnesiumsalz zur Verfügung zu stellen, welches dadurch gekennzeichnet ist, daß es als rieselfähiges, nicht hygroskopisches Granulat vorliegt. Dieses Granulat aus Kernen besteht aus mindestens 30 Gew.-% Magnesiumchloridkristallen aber keinen wesentlichen Mengen an Calciumsalzen, wobei die Granulatkörner ummantelt sind mit einem wasserlöslichen aber als Wasserdampfsperre wirkenden Filmüberzug.It is now possible to use a bath salt with a magnesium salt content to provide, which is characterized by is that it's as flowable, not hygroscopic Granules are present. This granulate consists of cores at least 30% by weight of magnesium chloride crystals but none substantial amounts of calcium salts, the granules are covered with a water-soluble but as Water vapor barrier film coating.
Aus den Erfahrungen mit Magnesiumchlorid-Salben ergab sich die weitergehende Aufgabe, diesem Badesalz zusätzlich Vitamin E und/oder ungesättigte Fettsäuren zuzusetzen. Da dies lipophile Substanzen sind, bereitet ihre Zumischung zu einem Badesalz besondere Schwierigkeiten.Experience with magnesium chloride ointments resulted in the further task, this bath salt additional vitamin Add E and / or unsaturated fatty acids. Because this is lipophilic Substances are prepared for their admixture Bath salts have particular difficulties.
Es ist jetzt gelungen, Vitamin E und/oder ungesättigte Fettsäuren in Form von wäßrigen Dispersionen einzusetzen und damit die Magnesiumchloridkristalle zu granulieren.It has now succeeded in vitamin E and / or unsaturated fatty acids use in the form of aqueous dispersions and to granulate the magnesium chloride crystals.
Um ein rascheres Auflösen des Badesalzes im Badewasser zu erzielen, hat es sich weiterhin als sehr wertvoll erwiesen, dem Badesalz Sprengmittel und/oder Brausehilfsstoffe zuzugeben. Dies ist insbesondere dann möglich, wenn das Sprengmittel und/oder die Brausehilfsstoffe in den Kernen der Granulatkörner vorliegen und das Vitamin E und/oder die ungesättigten Fettsäuren als Filmschicht zwischen den Kernen des Granulats vorliegen. Um die fettigen und öligen Filmschichten des Vitamin E und/oder der ungesättigten Fettsäuren anschließend mit einem wasserlöslichen aber als Wasserdampfsperre wirkenden Film überziehen zu können, empfiehlt es sich, das Granulat vor der Ummantelung abzustäuben. Besonders bewährt hat sich das Abstäuben mit feinteiligem Magnesiumlaktat, welches nach dem Auflösen des Badesalzes weitere Magnesiumionen für die Therapie zur Verfügung stellt.To dissolve the bath salt more quickly in the bath water , it has continued to be very valuable Add disintegrants and / or effervescent additives to the bath salt. This is particularly possible if the explosive and / or the effervescent aids in the cores of the Granules are present and the vitamin E and / or the unsaturated Fatty acids as a film layer between the cores of the Granules are present. To the greasy and oily layers of film of vitamin E and / or unsaturated fatty acids with a water-soluble but as a water vapor barrier It is recommended to be able to cover the acting film to dust off the granules before coating. Especially Dusting with finely divided magnesium lactate has proven itself, which after dissolving the bath salt more Provides magnesium ions for therapy.
Als Brausehilfsstoffe und/oder Sprengmittel können auch Gemische von Sprengmitteln mit Brausehilfsmitteln verwendet werden. Als Brausehilfsmittel kommen alle üblichen trockenen Gemische in Frage, die keine Calciumsalze enthalten. Bevorzugt verwendet wird das Gemisch aus Natriumhydrogencarbonat und Zitronensäure. Als Sprengmittel kommen vor allem Stoffe in Frage, die bei Berührung mit Wasser stark quellen. Hierzu gehören getrocknetes Agar-Agar und getrocknetes Guargum. Durch die starke Ausdehnung bei der Berührung mit Wasser helfen diese Sprengmittel, die wirksamen Komponenten rasch im Badewasser aufzulösen.Mixtures can also be used as effervescent agents and / or disintegrants of explosives used with effervescent aids become. All the usual dry aids come as effervescent aids Mixtures that do not contain calcium salts. Prefers the mixture of sodium hydrogen carbonate is used and citric acid. Substances are the main explosives in question, which swell strongly on contact with water. For this include dried agar and dried guar gum. Due to the strong expansion when it comes into contact with water these explosives help the effective components quickly dissolve in the bath water.
Da die wichtigsten Komponenten des erfindungsgemäßen Badesalzes Magnesiumchlorid und gegebenenfalls Magnesiumlaktat sind, sollte der Gehalt hiervon vorzugsweise mehr als 50 Gew.-% betragen. Je nach Art und Menge der sonstigen Zusatzstoffe wie Sprengmitteln, Brausehilfsstoffen, Vitamin E und/oder ungesättigten Fettsäuren beträgt somit der Gehalt des erfindungsgemäßen Badesalzes an Magnesiumchlorid 55 bis 95 Gew.-%. Bei Zusatz von Vitamin E und/oder ungesättigten Fettsäuren liegt deren Gehalt zwischen 0,5 und 10 Gew.-%. Mengen von 1,5 Gew.-% Vitamin E und 1 % ungesättigter Fettsäuren haben sich besonders bewährt. Der Gehalt an Sprengmitteln und/oder Brausehilfsmitteln liegt meist im Bereich zwischen 2 und 10 Gew.-%. Ein Gehalt von 5 Gew.-% Brausehilfsmittel hat sich besonders bewährt.Since the most important components of the bath salt according to the invention Magnesium chloride and optionally magnesium lactate the content thereof should preferably be more than 50 % By weight. Depending on the type and amount of other additives such as disintegrants, effervescent aids, vitamin E and / or unsaturated fatty acids is the content of the bath salt of magnesium chloride 55 to 95% by weight. With the addition of vitamin E and / or unsaturated Fatty acids have a content between 0.5 and 10% by weight. Amounts of 1.5% by weight of vitamin E and 1% of unsaturated fatty acids have proven particularly successful. The content of explosives and / or shower aids are usually in the range between 2 and 10% by weight. A content of 5% by weight effervescent aid has proven particularly successful.
Das Granulieren erfolgt vorzugsweise mit einer wäßrigen Suspension von dl-α-Tocopherolacetat in wasserdispergierbarer Form. Die ungesättigten Fettsäuren werden ebenfalls vorzugsweise als solubilisierte Komplexe mit Hydroalcohol eingesetzt. Als ungesättigte Fettsäuren werden vorzugsweise Linolsäure, Linolensäure und Arachidonsäure verwendet. Prinzipiell kommen aber auch alle anderen einfach oder mehrfach ungesättigten Carbonsäuren in Frage, die sich bei der Behandlung des atopischen Ekzems und Psoriaris bewährt haben.The granulation is preferably carried out with an aqueous suspension of dl-α-tocopherol acetate in water-dispersible Shape. The unsaturated fatty acids are also preferred used as solubilized complexes with hydroalcohol. Preferred unsaturated fatty acids are linoleic acid, Linolenic acid and arachidonic acid are used. in principle but also come all other mono- or polyunsaturated Carboxylic acids in question during treatment of atopic eczema and psoriaris.
Die Ummantelung der Granulatkörner mit einem wasserlöslichen aber als Wasserdampfsperre wirkenden Filmüberzug erfolgt beispielsweise mit einem Vinylpyrolidon-vinylacetat-copolymerisat gegebenenfalls unter Zusatz von Hydroxyethylcellulose, Ethylcellulose und/oder pyrogener Kieselsäure. Diese Substanzen lassen sich als alkoholisch-wäßrige Lösung aufsprühen und bilden nach dem Trocknen in Form eines Filmüberzugs einen ausgezeichneten Schutz gegen Feuchtigkeit.The coating of the granules with a water-soluble but acts as a water vapor barrier film coating for example with a vinyl pyrolidone-vinyl acetate copolymer optionally with the addition of hydroxyethyl cellulose, Ethyl cellulose and / or fumed silica. This Substances can be sprayed on as an alcoholic aqueous solution and form after drying in the form of a film coating excellent protection against moisture.
Das erfindungsgemäße Badesalz wird je nach Gehalt an Magnesiumchlorid in Mengen von 200 bis 500 g dem Badewasser (ca. 80 l) zugesetzt. Das Badewasser enthält somit das Magnesiumchlorid in Konzentrationen von weniger als 1 %. Dafür kann es aber über längerer Zeit gleichmäßig von der gesamten Haut aufgenommen werden, so daß es dort seine Wirksamkeit entfalten kann.The bath salt according to the invention is, depending on the magnesium chloride content in quantities of 200 to 500 g the bath water (approx. 80 l) added. The bath water thus contains the magnesium chloride in concentrations of less than 1%. For that can but evenly over the entire skin over a longer period of time be included so that it can develop its effectiveness there can.
Die gute Wirksamkeit des Magnesiumchlorids in dem erfindungsgemäßen Badesalz wurde zunächst getestet an der Hemmung des Crotonöl-induzierten Ohrödems bei Mäusen. Dazu wurden Zubereitungen, die jeweils 10 Gew.-% Magnesiumchlorid enthielten, vergleichend getestet mit aufgelösten Badesalzen, so daß jeweils eine Endkonzentration von ebenfalls 10 Gew.-% Magnesiumchlorid entstand.The good effectiveness of magnesium chloride in the invention Bath salt was first tested to inhibit the Croton oil-induced ear edema in mice. For this purpose, preparations each containing 10% by weight magnesium chloride, comparatively tested with dissolved bath salts, so that each have a final concentration of 10% by weight of magnesium chloride originated.
In dem Vergleich mit einbezogen wurden handelsübliche Badesalze mit einem Gehalt an Magnesiumsalzen und einen dem Toten Meer entsprechenden Gehalt an Calciumchlorid. Weiterhin verglichen wurden wäßrige Lösungen von Magnesiumchlorid und reines Natriumchlorid.Commercial bath salts were included in the comparison containing magnesium salts and one to the dead Corresponding content of calcium chloride. Further compared were aqueous solutions of magnesium chloride and pure sodium chloride.
Bei entzündlichen Hautkrankheiten haben epidermale Langerhans-Zellen
(ELZ) eine entscheidende pathogenetische Bedeutung.
Diese Zellen zählen zu den Antigen-präsentierenden Zellen.
Deren Aktivität wird maßgeblich durch ein Oberflächenenzym
bestimmt, eine ATPase. Die Hemmung dieses Enzyms bewirkt
eine Hemmung der Funktion der ELZ und damit eine verminderte
entzündliche Reaktion auf der Haut. Die Hemmwirkung von
Magnesium, dem erfindungsgemäßen Magnesiumbadesalz und anderen
vergleichbaren Badesalzen und Kochsalz wurden bestimmt.
Die Ergebnisse sind in den nachfolgenden Tabellen 1 und 2
zusammengestellt.
Epidermis wurde mit den o.g. Salzkonzentrationen 1 h bei
37°C inkubiert, und es wurde nachfolgend die ELZ pro 1 mm2
Epidermis bestimmt.
Erste Beobachtungen bei Patienten mit Neurodermitis und Schuppenflechte mit dem erfindungsgemäßen Badesalz im Badewasser haben sehr gute Erfolge gezeigt. Das erfindungsgemäße Badesalz, insbesondere unter Zusatz von Vitamin E und/oder ungesättigten Fettsäuren, ist somit hervorragend verträglich und wirksam.First observations in patients with eczema and psoriasis with the bath salt according to the invention in bath water have had very good results. The bath salt according to the invention, especially with the addition of vitamin E and / or unsaturated Fatty acids is therefore extremely well tolerated and effective.
Die Herstellung des erfindungsgemäßen Salzes erfolgt dadurch, daß zunächst das Magnesiumchlorid in kristalliner Form mit den Brausehilfsstoffen Natriumhydrogencarbonat und Zitronensäure vermischt wird. Dieses Gemisch wird mit einer wäßrigen Suspension von dl-α-Tocopherolacetat (wasserdispergierbar) und einem Hydroalcohol-solubilisierten Komplex von ungesättigten Fettsäuren (Linolsäure, Linolensäure und Arachidonsäure) auf die Pulvermischung aufgesprüht, wobei dieses granuliert wird. Dieses Material wird mit feinpulvrigen Magnesiumlaktat abgestäubt und anschließend mit einer wäßrigen Lösung von Vinylpyrolidon-vinylacetat-copolymerisat und Hydroxyethylcellulose ummantelt. Nach dem Trocknen hat sich ein Filmüberzug gebildet, der das Granulat gegen Luftfeuchtigkeit schützt und ihm eine hohe Stabilität verleiht. Beim Eingeben ins Wasser löst sich das Badesalz rasch unter leichtem Schäumen auf.The salt according to the invention is produced by that first the magnesium chloride in crystalline form with the effervescent additives sodium hydrogen carbonate and citric acid is mixed. This mixture is mixed with an aqueous Suspension of dl-α-tocopherol acetate (water dispersible) and a hydroalcohol-solubilized complex of unsaturated Fatty acids (linoleic acid, linolenic acid and arachidonic acid) sprayed onto the powder mixture, this granulating becomes. This material is made with fine powdered magnesium lactate dusted and then with an aqueous solution of Vinyl pyrolidone-vinyl acetate copolymer and hydroxyethyl cellulose jacketed. After drying, there is a film coating formed, which protects the granules against humidity and gives it great stability. When entering into Water quickly dissolves the bath salt with slight foaming on.
Einige typische Zusammensetzungen sind in den nachfolgenden Beispielen zusammengestellt:Some typical compositions are in the following Examples compiled:
70 Gew.-% Magnesiumchlorid, 10 Gew.-% Magnesiumlactat, 1,5 Gew.- % α-Tocopherolacetat CWS (entsprechend 0,7 Gew.-% α-Tocopherolacetat) und 1,0 Gew.-% Vit F Wasserlöslich (solubilisierter Komplex von ungesättigten Fettsäuren, insbesondere Linolsäure, Linolensäure und Arachidonsäure).70% by weight magnesium chloride, 10% by weight magnesium lactate, 1.5 % By weight α-tocopherol acetate CWS (corresponding to 0.7% by weight α-tocopherol acetate) and 1.0% by weight Vit F water-soluble (solubilized Complex of unsaturated fatty acids, in particular Linoleic acid, linolenic acid and arachidonic acid).
Die Granulatkörner wurden mit vier verschiedenen Filmüberzügen besprüht und getrocknet. The granules were covered with four different film coatings sprayed and dried.
Filmüberzugslösung 1 bestand aus Vinylpyrolidon-Vinylacetat Copolymerisat in wäßriger Lösung in Konzentrationen zwischen 1 und 5 Gew.-%. Dieser Filmüberzug zeigt eine sehr gute Wasserdurchlässigkeit.Film coating solution 1 consisted of vinyl pyrolidone vinyl acetate Copolymer in aqueous solution in concentrations between 1 and 5% by weight. This film cover shows a very good one Water permeability.
Filmüberzugslösung 2 enthielt zusätzlich 0,1 bis 2,5 Gew.-% hydrophob modifizierte Hydroxyethylcellulose.Film coating solution 2 additionally contained 0.1 to 2.5% by weight Hydrophobically modified hydroxyethyl cellulose.
Filmüberzugslösung 3 enthielt außer Vinylpyrolidon-Vinylacetat Copolymerisat 0,05 bis 2,5 Gew.-% Ethylcellulose. Dieses Gemisch wurde in 75 % wäßrigem Ethanol gelöst und versprüht.Film coating solution 3 contained vinylpyrolidone-vinyl acetate Copolymer 0.05 to 2.5 wt .-% ethyl cellulose. This The mixture was dissolved in 75% aqueous ethanol and sprayed.
Filmüberzugslösung 4 enthält außer Vinylpyrolidon-Vinylacetat Copolymerisat 0,05 bis 1,5 Gew.-% hydrophobe pyrogene Kieselsäure als wäßrige Suspension.Film coating solution 4 contains vinylpyrolidone-vinyl acetate Copolymer 0.05 to 1.5 wt .-% hydrophobic pyrogenic Silicic acid as an aqueous suspension.
Die Filmüberzüge 2 bis 4 zeigten gute aber unterschiedliche wasserdampfsperrende Wirkung.Film coatings 2 to 4 showed good but different ones water vapor barrier effect.
Eine weitere bevorzugte Zubereitung hat die Zusammensetzung
Diese Zubereitung wird wie weiter oben beschrieben hergestellt und ist lagerstabil, in Wasser gut auflösbar, gut wirksam und einwandfrei verträglich.This preparation is made as described above and is stable in storage, readily soluble in water, good effective and perfectly tolerated.
Claims (12)
- A bath salt having a magnesium salt content, characterized in that it is provided as a flowable, nonhygroscopic granulate and said granulate consists of cores containing at least 30 % by weight of magnesium chloride crystals but no substantial amounts of calcium salts, wherein the cores of the granulate are sheathed by a water-soluble film coating which, however, acts as a water vapour barrier.
- The bath salt according to claim 1, characterized in that it additionally contains vitamin E and/or unsaturated fatty acids.
- The bath salt according to claim 1 or 2, characterized in that it contains disintegrants and/or effervescent auxiliaries.
- The bath salt according to claim 2 or 3, characterized in that said disintegrant and/or said effervescent auxiliaries are provided in the cores of the granulate and said vitamin E and/or said unsaturated fatty acids are provided as a film layer between the cores of the granulate.
- The bath salt according to any one of claims 1 to 4, characterized in that the magnesium chloride content exceeds 50 % by weight.
- The bath salt according to any one of claims 1 to 5, characterized in that the magnesium chloride content is from 55 to 95 % by weight.
- The bath salt according to any one of claims 2 to 6, characterized in that the vitamin E and/or unsaturated fatty acid content is from 0.5 to 10 % by weight.
- The bath salt according to any one of claims 3 to 7, characterized in that the disintegrant and/or effervescent auxiliary content is from 2 to 10 % by weight.
- A process for manufacturing the bath salt according to claim 1, characterized in that crystalline magnesium chloride is granulated optionally in admixture with a disintegrant and/or effervescent auxiliary and then sheathed by a water-soluble film coating which, however, acts as a water-vapour barrier.
- The process according to claim 9, characterized in that an aqueous dispersion of vitamin E and/or unsaturated fatty acids is used in the granulation.
- The process according to claim 10, characterized in that a dusting is performed subsequent to the granulation but prior to the sheathing by said film coating.
- The process according to claim 11, characterized in that finely divided magnesium lactate is used for dusting.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4444668 | 1994-12-15 | ||
| DE4444668 | 1994-12-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0716851A1 EP0716851A1 (en) | 1996-06-19 |
| EP0716851B1 true EP0716851B1 (en) | 2003-08-06 |
Family
ID=6535867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95119285A Expired - Lifetime EP0716851B1 (en) | 1994-12-15 | 1995-12-07 | Bath salt containing a magnesium salt and its manufacture process |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0716851B1 (en) |
| AT (1) | ATE246487T1 (en) |
| DE (1) | DE59510759D1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259825A1 (en) * | 2002-12-19 | 2004-07-08 | Elisabeth Fleischmann | Ausleitungsbad |
| EP2149375A1 (en) * | 2008-07-28 | 2010-02-03 | Despharma Kft. | Compositions for the treatment of dermatological diseases, and uses thereof |
| GB2515071B (en) * | 2013-06-13 | 2015-12-09 | Reckitt Benckiser Brands Ltd | Novel composition for a foot-soaking bath |
| GB201404178D0 (en) | 2014-03-10 | 2014-04-23 | Cosmetic Warriors Ltd | Composition |
| US10549130B2 (en) | 2015-01-26 | 2020-02-04 | Nutraceutical Corporation | Magnesium bath salt |
| CN111265417B (en) * | 2020-02-12 | 2023-02-24 | 东莞市星泽日用品有限公司 | Moisture-proof coated bath salt ball and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0217975B1 (en) * | 1985-10-08 | 1991-12-04 | Psori-Med Ag | Salt mixture for the treatment of psoriasis and other skin diseases |
| JPH0735326B2 (en) * | 1990-12-28 | 1995-04-19 | 仁尾興産株式会社 | Bath additive |
-
1995
- 1995-12-07 EP EP95119285A patent/EP0716851B1/en not_active Expired - Lifetime
- 1995-12-07 DE DE59510759T patent/DE59510759D1/en not_active Expired - Lifetime
- 1995-12-07 AT AT95119285T patent/ATE246487T1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0716851A1 (en) | 1996-06-19 |
| DE59510759D1 (en) | 2003-09-11 |
| ATE246487T1 (en) | 2003-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT390372B (en) | USE OF SOLAR FILTERS FOR STABILIZING AND IMPROVING THE SKIN COMPATIBILITY OF PREPARATIONS CONTAINING BENZOYL PEROXYDE FOR LOCAL ACNE TREATMENT | |
| EP0556660B1 (en) | Utilisation of fatty alpha-hydroxy acids | |
| EP0045282B1 (en) | Antiherpes lipstick and its use in treating lips and other face parts attacked by herpes hominis | |
| DE2731520C3 (en) | Deodorant | |
| DE4305460C2 (en) | Pharmaceutical or cosmetic preparation containing enzymes, process for their preparation and their use | |
| EP1174130A2 (en) | Use of preparations of curcuma plants | |
| DE60000616T3 (en) | Mineral water containing compositions | |
| CH656307A5 (en) | PREPARATION FOR LOCAL ACNE TREATMENT. | |
| JPS5883648A (en) | Lanolin acid copper and local composition | |
| DE60132441T2 (en) | EXTRACT FROM A PLANT OF SPECIES OLEA EUROPAEA AS AN INHIBITOR OF NO SYNTHASE AND USES | |
| DE19814087A1 (en) | Moisture-activated therapeutic system | |
| CH662274A5 (en) | PHARMACEUTICAL CREAM OF OIL IN WATER TYPE. | |
| DE69839040T2 (en) | FOUNTAIN CRACK EXTRACT CONTAINING PREPARATION FOR EXTERNAL APPLICATION | |
| EP0716851B1 (en) | Bath salt containing a magnesium salt and its manufacture process | |
| EP0439640B1 (en) | Method for preparing agents for the therapy of skin diseases | |
| CH652027A5 (en) | DERMATOLOGICAL PREPARATION FOR TREATING SKIN LESIONS. | |
| DE2248240C3 (en) | Bis (N-oxypyridyl-2-thio) aluminum derivatives, processes for their preparation and cosmetic deodorizing antiperspirants containing them | |
| EP1591125A1 (en) | Pharmaceutical composition comprising extracts of lichens and hypericum | |
| DE102005008299A1 (en) | Cosmetic and/or dermatological formulation, useful as e.g. antiseptic, comprises metallic silver as active agent, auxiliary- and basic- materials | |
| DE60304478T2 (en) | TOPICAL COMPOSITION CONTAINING KETOPROFEN STABILIZED WITH SULISOBENZONE | |
| DE60110897T2 (en) | THE DUAL INHIBITOR OF THE CHOLESTERYLESTER AND WAXEST SYNTHESIS AVASIMIBE FOR THE TREATMENT OF DISEASES OF THE THROAT | |
| DE2447627B2 (en) | ANTIMICROBIAL PREPARATION | |
| DE10347824B4 (en) | Pharmaceutical or cosmetic composition for the treatment of the skin | |
| DE2612038A1 (en) | COSMETIC COMPOSITIONS | |
| DE2115116A1 (en) | Improved lubricants and methods for making the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT DE FR GB GR |
|
| 17P | Request for examination filed |
Effective date: 19960813 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RUGARD PHARMAZEUTIK GMBH & CO. KG |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KRUEGER GMBH & CO. KG |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Designated state(s): AT DE FR GB GR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REF | Corresponds to: |
Ref document number: 59510759 Country of ref document: DE Date of ref document: 20030911 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030403370 Country of ref document: GR |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) | ||
| ET | Fr: translation filed | ||
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20040507 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20091217 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20091221 Year of fee payment: 15 Ref country code: FR Payment date: 20100105 Year of fee payment: 15 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20091221 Year of fee payment: 15 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20101207 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101207 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110103 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101207 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110704 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20141222 Year of fee payment: 20 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 59510759 Country of ref document: DE |